Comparing our data for P + CHT with clinical trials is difficult, as these studies with pembrolizumab were conducted differently with respect to NSCLC histology, and in addition, the group with PD-L1 expression ≥ 50% was only a subgroup of the total sample in these studies 3, 4. Here, CD274 is linked to non-small cell lung carcinoma.